Skip to main
INSM
INSM logo

Insmed (INSM) Stock Forecast & Price Target

Insmed (INSM) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 60%
Buy 33%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Insmed Inc. has shown a positive outlook through the modest increase in revenue estimates for its Brensocatib product, with projections for 2033E POS-adjusted worldwide sales reaching approximately $8.5 billion, up from $7.3 billion. This revision reflects a growing confidence in the near- and long-term potential of both Brensocatib and other pipeline developments, including Treprostinil Palmitil Inhalation Powder for pulmonary hypertension. Additionally, the company has decreased the terminal decline rate in its discounted cash flow calculations, indicating sustained optimism regarding the long-term viability of its product offerings.

Bears say

Insmed Inc faces significant challenges regarding the timely enrollment and completion of clinical studies for its key products, ARIKAYCE, brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP), which could adversely impact the company's probability of success estimations and overall valuation. Furthermore, projections suggest that TPIP may not be able to enter the idiopathic pulmonary fibrosis (IPF) market before 2034, contingent upon the approval of Tyvaso in 2027, which raises concerns about the company's growth potential and market competition. These factors contribute to a negative outlook for Insmed's stock, as delays in clinical development and regulatory approvals could severely affect its financial performance and investor confidence.

Insmed (INSM) has been analyzed by 15 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 33% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insmed (INSM) Forecast

Analysts have given Insmed (INSM) a Buy based on their latest research and market trends.

According to 15 analysts, Insmed (INSM) has a Buy consensus rating as of Dec 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $186.13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $186.13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insmed (INSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.